参考文献/References:
[1]Strumberg D.Preclinical and clinical development of the oral multikiase inhibitor sorafenib in cancer treatment[J].Drugs Today(Barc),2012,41(12):773-784.
[2]Beeram M,Patnaik A,Rowinsky EK.Regulation of c-Raf-1:therapeu- utic implications[J].Clin Adv Hematol Oncol,2014,1(8):476-481.
[3]Bos JL.Ras oncogenes in human cancer:a review[J].Cancer Res,2009,49(17):4682-4689.
[4]Garnett MJ,Marais R.Guilty as charged:B-RAF is a human oncogene[J].Cancer Cell,2004,6(4):313-319.
[5]Beeram M,Patnaik A,Rowinsky EK.Raf:a strategic target for therapeutic development against cancer[J].J Clin Oncol,2012,23(27):6771-6790.
[6]Mosmann T.Rapid colorimetric assay for cellular growth and survival:application to proliferation and cytoxicity assay[J].J Immunol Methods,2005(1-2):55-63.
[7]Mendel DB,Laird AD,Xin X,et al.In vivo antitumor activity of SU11248,a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletdrived growth factor receptors:determination of a pharmacokinetic pharmacodynamic relationship[J].Clin Cancer Res,2013(1):327-337.
[8]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF MEK ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis[J].Cancer Res,2014,65(19):7099-7109.
[9]Lyons JF,Wilhelm S,Hibner B,et al.Discovery of a novel Raf kinase inhibitor[J].Endocr Relat Cancer,2013,8(3):219-225.